Efficacy of gadoxetic acid-enhanced MRI in assessing tumor regression after radiofrequency ablation for hepatocellular carcinoma - comparison with CT

Efficacy of gadoxetic acid-enhanced MRI in assessing tumor regression after radiofrequency ablation for hepatocellular carcinoma - comparison with CT - EARTH study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000004571

Enrollment

Registered

2010-11-20

Start date

2010-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with untreated HCC with a diameter of 30 mm or less. 2. Patients with HCC that is enhanced by contrast media in arterial phase of both dynamic CT and EOB-MRI. 3. Patients satisfying the following criteria within 2 months before RFA Platelet >= 50000/mm3 Serum bilirubin level =< 3 mg/dL Prothrombin activity >= 50%

Exclusion criteria

Exclusion criteria: 1. Patients having allergy to Gd. 2. Patients having allergy to iodine. 3. Patients with eGFR less than 30 mL/min/1.73 m2 4. Patients with sever heart or lung diseases 5. Patients with asthma 6. Patients with uncontrolled other malignancies

Design outcomes

Primary

Measure	Time frame
Assessment of RFA treatment	—

Countries

Japan

Outcome results